ASND - アセンディス・ファ―マ (Ascendis Pharma A/S)

ASNDのニュース

   Parametric Portfolio Associates LLC Increases Position in Ascendis Pharma A/S (NASDAQ:ASND)  2021/12/08 11:06:43 Transcript Daily
Parametric Portfolio Associates LLC increased its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 38.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,565 shares of the biotechnology companys stock after buying an additional 7,620 shares during the quarter. Parametric []
   Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14  2021/12/07 22:41:00 Ascendis Pharma
COPENHAGEN, Denmark , Dec. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will host a virtual R&D Program Update for the investment community on Tuesday, December 14, 2021 . The event will feature updates on Ascendis Pharmas endocrinology rare
   -$2.65 Earnings Per Share Expected for Ascendis Pharma A/S (NASDAQ:ASND) This Quarter  2021/12/07 17:48:41 Dakota Financial News
Equities analysts forecast that Ascendis Pharma A/S (NASDAQ:ASND) will announce earnings of ($2.65) per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Ascendis Pharma A/Ss earnings. The highest EPS estimate is ($2.16) and the lowest is ($3.05). Ascendis Pharma A/S posted earnings of ($3.15) per share in the []
   Ascendis Pharma A/S (NASDAQ:ASND) Expected to Announce Quarterly Sales of $4.34 Million  2021/12/07 17:48:41 Transcript Daily
Wall Street analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to announce $4.34 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Ascendis Pharma A/Ss earnings, with estimates ranging from $930,000.00 to $9.63 million. Ascendis Pharma A/S posted sales of $640,000.00 in the same quarter last year, []
   Ascendis Pharma A/S (ASND) Worth Considering For The Next Few Weeks  2021/12/04 12:00:00 Stocks Register
Ascendis Pharma A/S (NASDAQ:ASND) concluded the trading at $135.61 on Friday, December 03 with a fall of -7.05% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $145.89 and 5Y monthly beta was reading 0.79 with its price kept floating in the Ascendis Pharma A/S (ASND) Worth Considering For The Next Few Weeks Read More »
   JPMorgan Chase & Co. Sells 38,699 Shares of Ascendis Pharma A/S (NASDAQ:ASND)  2021/11/07 09:32:45 Transcript Daily
JPMorgan Chase & Co. decreased its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 87.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,789 shares of the biotechnology companys stock after selling 38,699 shares during the period. JPMorgan Chase & Co.s holdings []
   Stifel Financial Corp Sells 89 Shares of Ascendis Pharma A/S (NASDAQ:ASND)  2021/11/04 08:54:42 Transcript Daily
Stifel Financial Corp lessened its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 1.3% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,527 shares of the biotechnology companys stock after selling 89 shares during the quarter. Stifel Financial Corps holdings in Ascendis Pharma []
   This Beaten-Down Biotech Could Rebound Nicely, Says One Fund Manager  2021/10/26 15:22:00 MarketWatch
Ascendis Pharma has a promising treatment for a growth-hormone deficiency. Why a Putnam manager sees "pretty substantial upside."
   Ascendis Pharma A/S (NASDAQ:ASND) Stock Holdings Decreased by Lakewood Capital Management LP  2021/10/26 15:16:42 Transcript Daily
Lakewood Capital Management LP reduced its position in Ascendis Pharma A/S (NASDAQ:ASND) by 4.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 77,450 shares of the biotechnology companys stock after selling 4,000 shares during the period. Lakewood Capital Management []
   Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by California Public Employees Retirement System  2021/10/26 09:34:42 Dakota Financial News
California Public Employees Retirement System lowered its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 75.6% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 25,258 shares of the biotechnology companys stock after selling 78,118 shares during the quarter. California Public Employees Retirement Systems holdings in Ascendis Pharma A/S were worth $3,323,000 as []
   Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and TransCon™ CNP at the American Society for Bone & Mineral Research 2021 Annual Meeting  2021/09/30 20:01:00 Intrado Digital Media
– Late-breaking oral presentation will feature a comprehensive review of 58-week results from the company’s Phase 2 PaTH Forward Trial –
   Ascendis Pharma A/S Announces Share Repurchase Program  2021/09/29 20:01:00 Benzinga
COPENHAGEN, Denmark, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ: ASND ), a biopharmaceutical company that utilizes its innovative TransCon technologies to potentially create new treatments that make a meaningful difference in patients'' lives, today announced that its Board of Directors has authorized the Company to repurchase up to $25 million of the Company''s American Depositary Shares (ADS) (the Share Repurchase Program), each of which represents one ordinary share of Ascendis Pharma A/S. The program will be executed under Rules 10b-18 and 10b5-1 of the U.S. securities regulations. For that purpose, Ascendis Pharma A/S has appointed J.P. Morgan Securities LLC as agent to execute the program independently and without influence from Ascendis Pharma A/S. The purpose of the Share Repurchase Program is to acquire ADS needed in connection with the Company''s planned share-based incentive program. Under the agreement, J.P. Morgan Securities LLC will repurchase ADS on behalf of Ascendis Pharma A/S during the trading period starting November 1, 2021 and expected to end no later than December 31, 2021.
   Parathyroid Hormone Global Market Report 2021: COVID-19 Growth And Change To 2030  2021/09/27 11:35:00 Intrado Digital Media
Major players in the parathyroid hormone market are Pfizer Inc, Eli Lilly and Company, Radius Health Inc, Shire, Ascendis Pharma, Entera Bio Ltd. , and Extend Biosciences Inc. The global parathyroid hormone market is expected to grow from $1. Major players in the parathyroid hormone market are Pfizer Inc, Eli Lilly and Company, Radius Health Inc, Shire, Ascendis Pharma, Entera Bio Ltd. , and Extend Biosciences Inc. The global parathyroid hormone market is expected to grow from $1.
   Ascendis Pharma posts encouraging data from mid-stage TransCon PTH study  2021/09/22 20:44:33 Seeking Alpha
   Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks  2021/09/22 20:27:00 Intrado Digital Media
Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with observed bone turnover markers previously reported

calendar